SLC22A4: A Potential Drug Target and Biomarker (G6583)

Target Name: SLC22A4

NCBI ID: G6583

SLC22A4

SLC22A4: A Potential Drug Target and Biomarker

SLC22A4 (S22A4_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and pancreas. It is a member of the SLC22A4 gene family, which encodes a protein that is involved in the transport of various molecules across cell membranes. One of the most interesting aspects of SLC22A4 is its potential as a drug target or biomarker.

SLC22A4 has been shown to play a role in a variety of biological processes that are important for human health. For example, it is involved in the regulation of ion channels, which are responsible for the flow of electrical signals through cells. In addition, SLC22A4 has been shown to be involved in the transport of drugs across cell membranes, which could make it an attractive target for drug developers.

One of the key advantages of SLC22A4 as a drug target is its expression in a wide range of tissues, which makes it an attractive candidate for targeting a variety of diseases. For example, SLC22A4 has been shown to be expressed in the brain, which suggests that it may be involved in the development or progression of neurological disorders. In addition, SLC22A4 has been shown to be expressed in the heart, which suggests that it may be involved in the regulation of cardiovascular function.

In addition to its potential as a drug target, SLC22A4 has also been shown to be a potential biomarker for a variety of diseases. For example, SLC22A4 has been shown to be expressed in the pancreas, which suggests that it may be involved in the regulation of insulin secretion. In addition, SLC22A4 has been shown to be expressed in the liver, which suggests that it may be involved in the metabolism of drugs or other substances.

SLC22A4 is also of interest as a potential drug target because of its expression in the liver. The liver is a key organ that is involved in the metabolism of a wide variety of substances, including drugs. As such, SLC22A4 has been shown to be expressed in the liver, which suggests that it may be involved in the metabolism of drugs that are designed to interact with it. This could make it an attractive target for drugs that are intended to treat a wide range of diseases.

In conclusion, SLC22A4 is a protein that has been shown to play a role in a variety of biological processes that are important for human health. Its expression in a wide range of tissues makes it an attractive candidate for targeting a variety of diseases. In addition, SLC22A4 has also been shown to be a potential drug target and biomarker, which could make it an attractive target for drug developers and researchers. Further studies are needed to fully understand the role of SLC22A4 in human health and disease.

Protein Name: Solute Carrier Family 22 Member 4

Functions: Sodium-ion dependent transporter of various organic cationic compounds. A key substrate of this transporter is ergothioneine (ET) (PubMed:15795384). Able to transport carnitine, probably moving one sodium ion with one molecule of carnitine. Also transports tetraethylammonium (TEA) without the involvement of sodium. May also contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier (PubMed:35307651)

The "SLC22A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC22A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets